HSDVHK-NH2 (TFA)

HSDVHK-NH2 (TFA)

• UNSPSC Description: HSDVHK-NH2 TFA is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM)[1][2].
• Target Antigen: Integrin
• Type: Peptides
• Related Pathways: Cytoskeleton
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/hsdvhk-nh2-tfa.html
• Solubility: H2O
• Smiles: NCCCC[C@@H](C(N)=O)NC([C@H](CC1=CNC=N1)NC([C@H](C(C)C)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H](CC2=CNC=N2)N)=O)=O)=O)=O)=O.O=C(O)C(F)(F)F
• Molecular Weight: 834.80
• References & Citations: [1]Yoonsuk Lee, et al. High-throughput screening of novel peptide inhibitors of an integrin receptor from the hexapeptide library by using a protein microarray chip. J Biomol Screen. 2004 Dec;9(8):687-94.|[2]Youngjin Choi, et al. Site-specific inhibition of integrin alpha v beta 3-vitronectin association by a ser-asp-val sequence through an Arg-Gly-Asp-binding site of the integrin. Proteomics. 2010 Jan;10(1):72-80.|[3]Ji-Young Bang, et al. Pharmacoproteomic analysis of a novel cell-permeable peptide inhibitor of tumor-induced angiogenesis. Mol Cell Proteomics. 2011 Aug;10(8):M110.005264.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported